ABOUT ISGIDAR:
Dr. Richard A. Meisch
Department of Psychiatry
The University of Texas
Health Science Center at Houston
1300 Moursund
Houston, TX 77030-3497
713-794-1440

ABOUT ISGIDAR NEWSLETTER:
Dr. John R. Hughes
Human Behavioral Pharmacology Laboratory
Department of Psychiatry
University of Vermont
38 Fletcher Place
Burlington, Vermont 05401-1419
802-656-3065

Annual Meeting of the International Study Group Investigating Drugs as Reinforcers
Keystone Resort
Dillon, Colorado
June 20, 1992

John D. Roache, Melinda A. Stanley, and Daniel L. Cresson, University of Texas Health Science Center at Houston Diazepam-reinforced self-medication behavior in anxious patients.

Susan Schenk and Emily S. Davidson, Texas A&M University Variability in response to cocaine's reinforcing effects: Results of human and animal studies.

Student Travel Award: Richard J. DeGrandpre, University of Vermont Effects of income on drug choice in humans.

Frank George, University of New Mexico What is reinforcement? A genetic approach to questions in behavioral pharmacology.

Student Travel Award Finalist: Sharon Rosenzweig-Lipton, Harvard University The high-efficacy D1 dopamine receptor agonist SKF 81297 as a candidate therapeutic for cocaine dependence.

Nancy A. Ato and Roland R. Griffiths, Johns Hopkins University Oral alprazolam reinforcement in baboons.

Michael A. Nader, University of Chicago The effects of reinforcement schedule history on cocaine self-administration by rhesus monkeys.
Student Travel Award Finalist: Mary Ann D. Chuang, University of Chicago
Subjective effects of ethanol and diazepam: Correlates of drug self-administration.
John R. Hughes, Alison H. Owleso, Stephen T. Higgins, Warren K. Bickel, William Valliere and Sue Terry, University of Vermont. Caffeine as a reinforcer in 10-15 year old soda drinkers: Preliminary results.

Invited speaker: Tsutomu Suzuki, Hoshi University. Genetic differences in appetitive effect of abused drugs.

James P. Zainsy, University of Chicago. The subjective, cognitive and effects of subanesthetic doses of an intravenous general anesthetic, propofol, in healthy volunteers.

Richard A. Melsch, University of Texas Health Science Center at Houston. Orally self-administered cocaine in rhesus monkeys: Transition from negative or neutral behavioral effects to positive reinforcing effects.

Richard W. Fobin and Marian W. Fischman, Johns Hopkins University. Effects of a non-drug option on intravenous cocaine choice by humans.

ISGIDAR BUSINESS MEETING

Minutes of last year’s meeting were approved.

Dr. Melsch called the meeting to order at 4:25. The four nominees for membership in ISGIDAR were Leslie Amass, Jack Bergman, Pamela Doty and Ralph Spiga. All were voted in as members.

The treasurers report indicated that, after the fees and expenses for the meeting we should have a balance of around $5,000.

The meeting was attended by over 80 persons and was successful. A note was made to have coffee in the morning at registration at the next meeting.

Bill Woolverton reported that FDA had recently published guidelines for ethical animal practices. Interested members can contact Bill to examine and/or make comments on these guidelines. Dr. Woolverton also mentioned that the legislation to protect research facilities from attacks by animal rights movement persons is still in the House Judiciary Committee and those interested might want to write the members of that committee.

The format for having invited speakers and travel was discussed and the prior format was endorsed.

There was a discussion about changing the format of the meeting to fewer but longer papers, but this did not seem acceptable.

John Hughes discussed the possibility of ISGIDAR sponsoring a meeting on definitions of reinforcement. After much discussion, the consensus was that a meeting was in order and that it would be best done by collaborating with a NIDA technical review. There was no consensus as to whether the meeting should be combined with ISGIDAR or should be a separate meeting. John Hughes is to follow up on this.
MESSAGE FROM THE PRESIDENT

This year's meeting was well attended. Fourteen papers were presented. Seven papers concerned studies with human subjects, and similarly seven were studies with laboratory animals. The comments I received indicated that people enjoyed the meeting. More than 75 people attended, and 70 were present at the lunch. This level of participation and interest indicates that ISGIDAR continues to be a strong organization.

The FDA has published "Draft Guidelines for Good Academic Research Practices in Animal Pharmacology." Individuals interested in regulations regarding the testing of drugs in animals for pharmaceutical companies may wish to look at the Guidelines and submit their comments to the Director of the Pilot Drug Evaluation Staff, Food and Drug Administration. Copies of the Guidelines may be obtained from Dr. David A. Downs, Warner-Lambert/Parke-Davis, 2800 Plymouth Road, Ann Arbor, Michigan 48105.

Two Japanese companies, Taisha Pharmaceutical Co., Ltd and Shionogi & Co., Ltd., donated money to ISGIDAR and because of this donation we were able to give extra travel support to Dr. Suzuki who was our invited speaker at the 1992 meeting. We are very appreciative of their support.
The 1993 ISGIDAR meeting will be held on Saturday, June 12th at the Toronto Hilton. As in the past, ISGIDAR will be conducted as a satellite session of the Committee on Problems of Drug Dependence. Note that the meeting will be held on Saturday.

INVITED SPEAKERS FOR THE 1993 MEETING

We are seeking suggestions for speakers to invite to the 1993 meeting. Invited speakers should be individuals who do not regularly attend the ISGIDAR meeting, and who are doing interesting research related to drugs as reinforcers. They will be paid a $100 honorarium. Members are urged to submit suggestions to Richard Meisch.

1993 TRAVEL AWARD: STUDENT PAPER COMPETITION

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to $500 in reasonable and documented travel costs will be paid to the winner to attend the meeting of the Committee on Problems of Drug Dependence, 1993 to present a paper at the ISGIDAR satellite session. Payment will be made upon submission of travel receipts to the ISGIDAR Treasurer. Those who did not receive the award, but who did receive good reviews will be encouraged to present their papers at the ISGIDAR meeting.

ELIGIBILITY: Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1987).

Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member.

The research to be reported at ISGIDAR must not already be published.

MANUSCRIPT REQUIREMENTS: Papers should not be more than 10 pages excluding figures and references.

The length and scope of the paper should be consistent with a 20-25 minute slide presentation. Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript.

The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research.

Submit four copies, double-spaced.

REVIEW: Each manuscript will be independently reviewed by the ISGIDAR officers for originality, scientific contribution, sound methodology and clarity of the manuscript.
Blind review is possible upon request.

Reviewers will not participate in the review of papers from their own institution.

Submit manuscripts to

Dr. Richard A. Melosh
Department of Psychiatry and Behavioral Sciences
University of Texas Health Science Center at Houston
1300 Moursund St.
Houston, Texas 77030-3497

DEADLINE FOR SUBMISSION: April 15, 1993

POSTDOCTORAL FELLOWSHIPS

Johns Hopkins University School of Medicine

Postdoctoral fellowships are available at the Johns Hopkins University School of Medicine to develop and implement human behavioral pharmacology research -- in both laboratory and clinic -- related to substance abuse. Stimulating and productive environment. Projects include evaluation of behavioral and pharmacological treatments, drug interaction studies related to medications development; also, drug discrimination, abuse liability assessment, physical dependence, performance effects, contingency management, behavioral counseling, smoking cessation. Broad range of substances under study: opioids, cocaine, sedatives, tobacco, marijuana, caffeine. Ph.D. in experimental or clinical; research experience desirable. Stipend: USPHS levels, based on experience. Minorities encouraged. Send letter of interest, vite, and phone numbers of three references to: George E. Bigelow, Ph.D., BPRU/Psychiatry, D-3-W, Johns Hopkins/Key Medical Center; 4540 Eastern Avenue; Baltimore, MD 21224; (301) 550-9035.

University of Texas Health Science Center-Houston, School of Medicine, Substance Abuse Research Center.

Postdoctoral positions in Behavioral Pharmacology supported by a NIDA Training Grant awarded to the Substance Abuse Research Center (SARC) at the University of Texas Health Science Center at Houston. SARC consists of 12 faculty members actively engaged in research supported by nine NIH grants and a drug contract. Three components of SARC are involved in training: (1) the Addictive Behaviors Clinic with a staff of five counselors and two nurses, (2) the Human Behavioral Pharmacology Laboratory containing 13 human operant chambers, and (3) the Preclinical Laboratories which have a large facility for rodent and primate research. Most of the research activities are concerned with the treatment of substance abusers, the study of human and animal drug self-administration, and the study of drug effects upon human and animal behavior. Interested individuals should send a c.v. and letter of interest to: John Grabowski, Ph.D. (Clinical research/human drug self-administration), Richard Meisch, M.D., Ph.D. (animal drug self-administration), Don R. Cherek, Ph.D. (human behavioral pharmacology) or Peter B. Silverman, Ph.D. (animal behavioral pharmacology) at Substance Abuse Research Center, Department of Psychiatry & Behavioral Sciences, Univ. Texas Health Science Center, 1300 Moursund St., Houston, TX 77030-3497. (713)-782-7925.
Medical College of Virginia

One or more postdoctoral fellowship or research associate positions in the behavioral pharmacology laboratories of Drs. Robert Balster and Robert Manisbach will be opening during 1992-93. Research methods include operant behavior and drug discrimination in mice, rats, squirrel monkeys and rhesus monkeys, i.v. drug self-administration in rhesus monkeys, and startle responding in rats and mice. Areas of research include the behavioral relevance of amino acid receptor activation and antagonists, the development and use of animal models for assessing new pharmacotherapies for substance abuse, the discriminative stimulus and reinforcing properties of cocaine, the behavioral effects of abused inhalants, and drug abuse potential evaluation. Send vita and letter describing research interests to Drs. Balster or Manisbach, Department of Pharmacology and Toxicology, Medical College of Virginia, Richmond, VA 23298-0613.

ISIGIDAR BIBLIOGRAPHY

Listing of recent publications or manuscripts in press on the behavioral pharmacology of drugs of abuse by ISIGIDAR members:

R = published, reprints available
P = in press
S = submitted
N = published, reprints not available

Dr. Robert L. Balster
Department of Pharmacology and Toxicology
Medical College of Virginia
Box 613
Richmond, VA 23298-0613


Dr. Warren K. Bickel
Human Behavioral Pharmacology Laboratory
Department of Psychiatry
University of Vermont
38 Fletcher Place
Burlington, VT 05401-1419


Dr. Hamlet deWit
Department of Psychiatry
The University of Chicago
5841 S. Maryland Avenue
Chicago, IL 60637


Roland R. Griffiths, Ph.D.
Behavioural BIOLOGY Research Center.
TSKMC/Johns Hopkins
5140 Nathan Shock Drive, Suite 3000
Baltimore, MD 21224


Dr. John R. Hughes
Human Behavioral Pharmacology Laboratory
Department of Psychiatry
University of Vermont
38 Fletcher Place
Burlington, Vermont 05401-1+19


R.H. Rech
Department of Pharmacology and Toxicology
B-440 Life Sciences Building
Michigan State University
East Lansing, MI 48824


Dr. T.S. Shippenberg
Addiction Research Center
NIDA
PO Box 5180
Baltimore, MD 21224


Dr. William Woolverton
Department of Psychiatry
The University of Chicago
5841 S. Maryland Avenue
Chicago, IL 60637


Kleven, M.S., Woolverton, W.L. Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug and Alcohol Dependence. (IP)


Dr. James P. Zachy
Department of Psychiatry
The University of Chicago
5841 S. Maryland Avenue
Chicago, IL 60637


ISGIDAR BIBLIOGRAPHY FORM

(RA) Published, reprints available
(IP) In Press, reprints will be mailed after publication
(NA) Reprints unavailable
(SU) Submitted

In submitting your entries, use any useful format. Mail this form to:

Dr. John R. Hughes
Human Behavioral Pharmacology Laboratory
Department of Psychiatry
University of Vermont
38 Fletcher Place
Burlington, Vermont 05401

Note: If the response cost is less to just mail a copy of the preprint or reprint, please feel free to do so with ISGIDAR written on the envelope or the paper itself.

Address for reprints:


Citations (in alphabetical order)